Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Quince Therapeutics Inc (QNCX)

Quince Therapeutics Inc (QNCX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,791
  • Shares Outstanding, K 55,681
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,830 K
  • EBIT $ -51 M
  • EBITDA $ -36 M
  • 60-Month Beta 1.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.40
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.21
  • Most Recent Earnings $-0.25 on 11/12/25
  • Next Earnings Date 03/23/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 685.80% (+167.41%)
  • Historical Volatility 872.51%
  • IV Percentile 96%
  • IV Rank 81.57%
  • IV High 816.55% on 01/29/26
  • IV Low 107.32% on 07/09/25
  • Expected Move (DTE 9) 0.2720 (250.46%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 336
  • Volume Avg (30-Day) 2,097
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 164,144
  • Open Int (30-Day) 177,802
  • Expected Range 0.0000 to 0.3806

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +356,885.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0880 +23.41%
on 03/03/26
0.4150 -73.83%
on 02/12/26
-0.5014 (-82.20%)
since 02/11/26
3-Month
0.0880 +23.41%
on 03/03/26
4.5499 -97.61%
on 12/12/25
-4.2914 (-97.53%)
since 12/11/25
52-Week
0.0880 +23.41%
on 03/03/26
4.5499 -97.61%
on 12/12/25
-1.3314 (-92.46%)
since 03/11/25

Most Recent Stories

More News
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics, Inc. (Nasdaq: QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in its restructuring and evaluation of strategic alternatives...

QNCX : 0.1086 (+4.42%)
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Primary and key secondary endpoint did not achieve statistical significance eDSP was generally well tolerated with no clinically meaningful safety concerns identified...

QNCX : 0.1086 (+4.42%)
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster...

QNCX : 0.1086 (+4.42%)
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the last...

QNCX : 0.1086 (+4.42%)
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication...

QNCX : 0.1086 (+4.42%)
Quince Therapeutics to Participate at Investor Events in December 2025

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that senior...

QNCX : 0.1086 (+4.42%)
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T remains on track with topline results expected in first quarter of 2026

QNCX : 0.1086 (+4.42%)
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

No safety concerns identified by independent data and safety monitoring board, which recommends continuation of study without any modifications

QNCX : 0.1086 (+4.42%)
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster...

QNCX : 0.1086 (+4.42%)
Oppenheimer Sticks to Their Buy Rating for Quince Therapeutics (QNCX)

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Quince Therapeutics, with a price target of $10.00. The company’s shares closed yesterday at $1.64.Elevate Your...

QNCX : 0.1086 (+4.42%)

Business Summary

Quince Therapeutics Inc. is a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases. The company's product pipeline includes NOV004. Quince Therapeutics Inc., formerly known as Cortexyme Inc., is based in Calif.

See More

Key Turning Points

3rd Resistance Point 0.1368
2nd Resistance Point 0.1299
1st Resistance Point 0.1192
Last Price 0.1086
1st Support Level 0.1016
2nd Support Level 0.0947
3rd Support Level 0.0840

See More

52-Week High 4.5499
Fibonacci 61.8% 2.8455
Fibonacci 50% 2.3189
Fibonacci 38.2% 1.7924
Last Price 0.1086
52-Week Low 0.0880

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar